BioLargo reports record Q1 revenue, positive operating cash flow of $481K

BIOLARGO, INC.

Q1 2024 revenue $4.76M, up 28% YoY and 9% QoQ; generated $481K positive operating cash flow.
Net loss $775K including $623K non-cash equity comp; stockholder's equity rose from $4.2M to $5.1M.
Launched water equipment subsidiary for PFAS treatment; appointed Sally Gutierrez, Jeffrey Kightlinger, Larry Dick to board.
EPA finalized PFAS regulations expected to favor BioLargo's treatment technology due to high efficacy and low waste.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.